Overview

Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)

Status:
Completed

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

Summary

This randomized, double-blind, placebo-controlled, multicenter, 8-week, clinical trial is designed to assess the efficacy and safety of vilazodone and to evaluate genetic biomarkers of treatment response associated with vilazodone use in adult patients diagnosed with MDD by the DSM-IV-TR criteria.

Phase:

Phase 3

Details

Lead Sponsor:

Forest Laboratories

Treatments:

Vilazodone Hydrochloride